New Ph III results bode well for tiotropium in previously treated asthma
This article was originally published in Scrip
Boehringer Ingelheim's long-acting bronchodilator tiotropium delivered once-daily with the Respimat inhaler showed statistically significant improvements in lung function and reduced the incidence of asthma exacerbations in the first two of several Phase III studies under the company's UniTinA-asthma programme.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.